United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
284.73
-0.46 (-0.16%)
Apr 17, 2025, 4:00 PM EDT - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 388.25, with a low estimate of 280 and a high estimate of 600. The average target predicts an increase of 36.36% from the current stock price of 284.73.
Analyst Consensus: Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for United Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Buy | 6 | 6 | 5 | 3 | 3 | 3 |
Hold | 2 | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 15 | 15 | 14 | 12 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $425 | Strong Buy | Reiterates | $425 | +49.26% | Feb 27, 2025 |
UBS | UBS | Strong Buy Maintains $415 → $475 | Strong Buy | Maintains | $415 → $475 | +66.82% | Jan 8, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $243 → $302 | Hold | Maintains | $243 → $302 | +6.07% | Nov 1, 2024 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $319 → $344 | Strong Buy | Maintains | $319 → $344 | +20.82% | Oct 31, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $575 → $600 | Buy | Maintains | $575 → $600 | +110.73% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
3.21B
from 2.88B
Increased by 11.52%
Revenue Next Year
3.40B
from 3.21B
Increased by 6.08%
EPS This Year
28.19
from 24.64
Increased by 14.41%
EPS Next Year
29.19
from 28.19
Increased by 3.54%
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.5B | 3.7B | 4.6B | ||
Avg | 3.2B | 3.4B | 3.6B | ||
Low | 2.9B | 2.9B | 2.7B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 20.4% | 16.6% | 34.9% | ||
Avg | 11.5% | 6.1% | 6.1% | ||
Low | -0.8% | -10.3% | -20.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 31.50 | 32.90 | 41.06 | ||
Avg | 28.19 | 29.19 | 30.26 | ||
Low | 23.03 | 21.87 | 17.80 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 27.8% | 16.7% | 40.7% | ||
Avg | 14.4% | 3.5% | 3.7% | ||
Low | -6.5% | -22.4% | -39.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.